Cargando…

In Vitro activity of a Novel Benzoquinolizine Antibiotic, Levonadifloxacin (WCK 771) against Blood Stream Gram-Positive Isolates from a Tertiary Care Hospital

Background  Blood stream infections (BSIs) due to Gram-positive pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) are associated with high mortality ranging from 10 to 60%. The current anti-MRSA agents have limitations with regards to safety and tolerability profile which limits t...

Descripción completa

Detalles Bibliográficos
Autores principales: Mamtora, Dhruv, Saseedharan, Sanjith, Rampal, Ritika, Joshi, Prashant, Bhalekar, Pallavi, Ahdal, Jaishid, Jain, Rishi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Thieme Medical and Scientific Publishers Pvt. Ltd. 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7684988/
https://www.ncbi.nlm.nih.gov/pubmed/33268943
http://dx.doi.org/10.1055/s-0040-1720944
_version_ 1783613108819853312
author Mamtora, Dhruv
Saseedharan, Sanjith
Rampal, Ritika
Joshi, Prashant
Bhalekar, Pallavi
Ahdal, Jaishid
Jain, Rishi
author_facet Mamtora, Dhruv
Saseedharan, Sanjith
Rampal, Ritika
Joshi, Prashant
Bhalekar, Pallavi
Ahdal, Jaishid
Jain, Rishi
author_sort Mamtora, Dhruv
collection PubMed
description Background  Blood stream infections (BSIs) due to Gram-positive pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) are associated with high mortality ranging from 10 to 60%. The current anti-MRSA agents have limitations with regards to safety and tolerability profile which limits their prolonged usage. Levonadifloxacin and its oral prodrug alalevonadifloxacin, a novel benzoquinolizine antibiotic, have recently been approved for acute bacterial skin and skin structure infections including diabetic foot infections and concurrent bacteremia in India. Methods  The present study assessed the potency of levonadifloxacin, a novel benzoquinolizine antibiotic, against Gram-positive blood stream clinical isolates ( n = 31) collected from January to June 2019 at a tertiary care hospital in Mumbai, India. The susceptibility of isolates to antibacterial agents was defined following the Clinical and Laboratory Standard Institute interpretive criteria (M100 E29). Results  High prevalence of MRSA (62.5%), quinolone-resistant Staphylococcus aureus (QRSA) (87.5%), and methicillin-resistant coagulase-negative staphylococci (MR-CoNS) (82.35%) were observed among bacteremic isolates. Levonadifloxacin demonstrated potent activity against MRSA, QRSA, and MR-CoNS strains with significantly lower minimum inhibitory concentration MIC (50/90) values of 0.5/1 mg/L as compared with levofloxacin (8/32 mg/L) and moxifloxacin (2/8 mg/L). Conclusion  Potent bactericidal activity coupled with low MICs support usage of levonadifloxacin for the management of BSIs caused by multidrug resistant Gram-positive bacteria.
format Online
Article
Text
id pubmed-7684988
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Thieme Medical and Scientific Publishers Pvt. Ltd.
record_format MEDLINE/PubMed
spelling pubmed-76849882020-12-01 In Vitro activity of a Novel Benzoquinolizine Antibiotic, Levonadifloxacin (WCK 771) against Blood Stream Gram-Positive Isolates from a Tertiary Care Hospital Mamtora, Dhruv Saseedharan, Sanjith Rampal, Ritika Joshi, Prashant Bhalekar, Pallavi Ahdal, Jaishid Jain, Rishi J Lab Physicians Background  Blood stream infections (BSIs) due to Gram-positive pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) are associated with high mortality ranging from 10 to 60%. The current anti-MRSA agents have limitations with regards to safety and tolerability profile which limits their prolonged usage. Levonadifloxacin and its oral prodrug alalevonadifloxacin, a novel benzoquinolizine antibiotic, have recently been approved for acute bacterial skin and skin structure infections including diabetic foot infections and concurrent bacteremia in India. Methods  The present study assessed the potency of levonadifloxacin, a novel benzoquinolizine antibiotic, against Gram-positive blood stream clinical isolates ( n = 31) collected from January to June 2019 at a tertiary care hospital in Mumbai, India. The susceptibility of isolates to antibacterial agents was defined following the Clinical and Laboratory Standard Institute interpretive criteria (M100 E29). Results  High prevalence of MRSA (62.5%), quinolone-resistant Staphylococcus aureus (QRSA) (87.5%), and methicillin-resistant coagulase-negative staphylococci (MR-CoNS) (82.35%) were observed among bacteremic isolates. Levonadifloxacin demonstrated potent activity against MRSA, QRSA, and MR-CoNS strains with significantly lower minimum inhibitory concentration MIC (50/90) values of 0.5/1 mg/L as compared with levofloxacin (8/32 mg/L) and moxifloxacin (2/8 mg/L). Conclusion  Potent bactericidal activity coupled with low MICs support usage of levonadifloxacin for the management of BSIs caused by multidrug resistant Gram-positive bacteria. Thieme Medical and Scientific Publishers Pvt. Ltd. 2020-12 2020-11-23 /pmc/articles/PMC7684988/ /pubmed/33268943 http://dx.doi.org/10.1055/s-0040-1720944 Text en The Indian Association of Laboratory Physicians. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.) https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited.
spellingShingle Mamtora, Dhruv
Saseedharan, Sanjith
Rampal, Ritika
Joshi, Prashant
Bhalekar, Pallavi
Ahdal, Jaishid
Jain, Rishi
In Vitro activity of a Novel Benzoquinolizine Antibiotic, Levonadifloxacin (WCK 771) against Blood Stream Gram-Positive Isolates from a Tertiary Care Hospital
title In Vitro activity of a Novel Benzoquinolizine Antibiotic, Levonadifloxacin (WCK 771) against Blood Stream Gram-Positive Isolates from a Tertiary Care Hospital
title_full In Vitro activity of a Novel Benzoquinolizine Antibiotic, Levonadifloxacin (WCK 771) against Blood Stream Gram-Positive Isolates from a Tertiary Care Hospital
title_fullStr In Vitro activity of a Novel Benzoquinolizine Antibiotic, Levonadifloxacin (WCK 771) against Blood Stream Gram-Positive Isolates from a Tertiary Care Hospital
title_full_unstemmed In Vitro activity of a Novel Benzoquinolizine Antibiotic, Levonadifloxacin (WCK 771) against Blood Stream Gram-Positive Isolates from a Tertiary Care Hospital
title_short In Vitro activity of a Novel Benzoquinolizine Antibiotic, Levonadifloxacin (WCK 771) against Blood Stream Gram-Positive Isolates from a Tertiary Care Hospital
title_sort in vitro activity of a novel benzoquinolizine antibiotic, levonadifloxacin (wck 771) against blood stream gram-positive isolates from a tertiary care hospital
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7684988/
https://www.ncbi.nlm.nih.gov/pubmed/33268943
http://dx.doi.org/10.1055/s-0040-1720944
work_keys_str_mv AT mamtoradhruv invitroactivityofanovelbenzoquinolizineantibioticlevonadifloxacinwck771againstbloodstreamgrampositiveisolatesfromatertiarycarehospital
AT saseedharansanjith invitroactivityofanovelbenzoquinolizineantibioticlevonadifloxacinwck771againstbloodstreamgrampositiveisolatesfromatertiarycarehospital
AT rampalritika invitroactivityofanovelbenzoquinolizineantibioticlevonadifloxacinwck771againstbloodstreamgrampositiveisolatesfromatertiarycarehospital
AT joshiprashant invitroactivityofanovelbenzoquinolizineantibioticlevonadifloxacinwck771againstbloodstreamgrampositiveisolatesfromatertiarycarehospital
AT bhalekarpallavi invitroactivityofanovelbenzoquinolizineantibioticlevonadifloxacinwck771againstbloodstreamgrampositiveisolatesfromatertiarycarehospital
AT ahdaljaishid invitroactivityofanovelbenzoquinolizineantibioticlevonadifloxacinwck771againstbloodstreamgrampositiveisolatesfromatertiarycarehospital
AT jainrishi invitroactivityofanovelbenzoquinolizineantibioticlevonadifloxacinwck771againstbloodstreamgrampositiveisolatesfromatertiarycarehospital